Research peptide vials and HPLC laboratory equipment for retatrutide triple agonist study — Arma Peptides UK
Retatrutide UK: Complete Research Guide to the Triple Agonist Peptide 2026
📅 May 2026⏱ 11 min read🔬 Research Use Only
A single Phase 2 trial published in The New England Journal of Medicine (June 2023) changed the metabolic research landscape: retatrutide delivered up to 24.2% body weight reduction at 48 weeks — a magnitude not previously observed with any single GLP-1 receptor agonist compound. At higher doses, 48-week data pushed beyond that figure, outpacing both semaglutide (STEP 1: ~15%) and tirzepatide (SURMOUNT-1: ~21%) in head-to-head trajectory. For UK laboratory researchers investigating metabolic signalling pathways, receptor pharmacology, or adipose biology, retatrutide represents the most mechanistically distinct research compound currently available from verified suppliers.
This guide covers the full pharmacological profile of retatrutide — its triple-receptor agonism across GLP-1, GIP, and glucagon pathways — alongside Phase 2 trial data, comparison benchmarks against predecessor compounds, and practical sourcing guidance for UK-based laboratories. All compounds referenced are supplied exclusively for in vitro and preclinical research use only.
Table of Contents
- Quick Takeaways
- What Is Retatrutide? Mechanism & Receptor Profile
- Phase 2 NEJM 2023: Key Trial Data
- Retatrutide vs Semaglutide vs Tirzepatide: Research Comparison
- Why the Glucagon Receptor Changes Everything
- Supplier Comparison Table
- Retatrutide REVYTAL 30MG — Arma Peptides Product Section
- Laboratory Sourcing Checklist
- FAQs
Quick Takeaways
| Key Point | What It Means |
|---|---|
| Triple-receptor agonist | Simultaneously activates GLP-1R, GIPR, and glucagon receptor — no approved or widely available research compound shares this tri-pathway profile |
| 24.2% weight reduction @ 48wk | Phase 2 NEJM data (2023) at the 12mg dose group; exceeds semaglutide (~15%) and tirzepatide (~21%) Phase 2/3 benchmarks |
| GLP-3 colloquial label | Researchers informally refer to retatrutide as a “GLP-3” agonist due to its three-target mechanism — useful for distinguishing it from dual-agonist predecessors |
| Half-life & dosing interval | Engineered C20 fatty acid tail confers ~6-day half-life enabling once-weekly subcutaneous administration in trial models |
| Hepatic lipid reduction | Glucagon receptor activation drives direct hepatic fat oxidation — a mechanistic advantage over GLP-1-only agonists in NAFLD/NASH research models |
| Lyophilized powder format | Arma Peptides supplies retatrutide as freeze-dried lyophilized powder — optimal for laboratory reconstitution and long-term stability at −20°C |
| Third-party verified CoA | Every Arma Peptides batch ships with an independent CoA (≥99% HPLC purity). UK Peptides, by contrast, publicly states on their own blog they do not use third-party lab testing |
| Research-use only | Retatrutide is not licenced by the MHRA or any regulatory authority for human use. All discussion herein relates strictly to preclinical and in vitro research applications |
What Is Retatrutide? Mechanism & Receptor Profile
Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide developed by Eli Lilly & Company. It was derived from a glucose-dependent insulinotropic polypeptide (GIP) backbone and subsequently engineered with non-coded residues — specifically Aib2, Aib20, and α-methyl leucine at position 13 — to improve metabolic stability and receptor binding kinetics. A C20 fatty acid moiety attached via a γGlu-miniPEG linker provides the extended half-life (~6 days) that supports once-weekly dosing protocols in research models.
Three-Receptor Activation
What distinguishes retatrutide from every predecessor compound in this research class is the simultaneous, balanced activation of three distinct receptors:
- GLP-1 Receptor (GLP-1R) — Primary satiety signalling, gastric emptying delay, incretin-mediated insulin secretion
- GIP Receptor (GIPR) — Amplified insulin secretion, adipose lipid partitioning, central appetite modulation
- Glucagon Receptor (GCGR) — Hepatic gluconeogenesis suppression, direct hepatic fat oxidation, energy expenditure upregulation
Semaglutide engages one receptor (GLP-1R). Tirzepatide engages two (GLP-1R + GIPR). Retatrutide engages all three — which is why researchers colloquially call it a “GLP-3 agonist”, and why its trial-observed efficacy consistently exceeds both predecessors. Structural insights into this triple agonism were published in Nature Communications (2024), confirming the molecular basis for retatrutide’s superior binding profile across all three receptor targets.
Physicochemical Properties Relevant to Laboratory Research
| Property | Value |
|---|---|
| CAS Number | 2381089-83-2 |
| Molecular Formula | C₂₁₃H₃₃₂N₅₆O₆₅ |
| Molecular Weight | ~4,762 Da |
| Half-life (in vivo model) | ~6 days (C20 fatty acid conjugate) |
| Standard Format | Lyophilized powder |
| Reconstitution | Bacteriostatic water or sterile water (research) |
| Storage (lyophilized) | −20°C, protect from light |
| Receptor targets | GLP-1R, GIPR, GCGR |
Phase 2 NEJM 2023: Key Trial Data
The landmark retatrutide Phase 2 randomised controlled trial was published in The New England Journal of Medicine on 26 June 2023 (DOI: 10.1056/NEJMoa2301972). It enrolled adults with obesity (BMI ≥30 or ≥27 with comorbidity), testing five once-weekly subcutaneous dose groups against placebo over 48 weeks. The following data points are of direct relevance to researchers establishing reference benchmarks:
| Dose Group | Mean Weight Change @ 24wk | Mean Weight Change @ 48wk | ≥10% Loss (48wk) | ≥15% Loss (48wk) |
|---|---|---|---|---|
| 1mg | −8.7% | −− | − | − |
| 4mg | −11.6% | −17.3% | ~62% | ~37% |
| 8mg | −14.9% | −22.8% | ~80% | ~65% |
| 12mg | −17.5% | −24.2% | ~85% | ~76% |
| Placebo | −2.1% | −2.1% | − | − |
At the highest dose (12mg), approximately 85% of participants achieved ≥10% weight reduction and 76% achieved ≥15% — response rates substantially exceeding those reported in STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) under comparable trial conditions. Subsequent data from extended modelling suggest that dose trajectory beyond 48 weeks may push percentage reductions toward the 28–30% range, making retatrutide the highest-efficacy compound of its class currently in active clinical development.
Researcher Note: The Phase 2 data also documented significant reductions in waist circumference (up to −25.1cm at 48wk, 12mg group) and fasting insulin levels. The glucagon receptor component was separately associated with reduced hepatic fat fraction — a finding of direct relevance to NAFLD/NASH research programmes. Phase 3 trials (TRIUMPH programme) are ongoing.
Retatrutide vs Semaglutide vs Tirzepatide: Research Comparison
Researchers selecting between these three compound classes for metabolic research programmes need a clear framework for mechanistic differentiation. This is not a trivial distinction: the receptor target profile directly determines which signalling cascades are activated, which experimental readouts are meaningful, and which research hypotheses each compound can validly address.
For UK laboratory researchers, Arma Peptides stocks all three classes: SLIMERIX™ 5MG (Semaglutide) — £120, ZONJERO 30MG (Tirzepatide) — £130, and RETATRUTIDE REVYTAL 30MG — £130 — enabling direct side-by-side experimental design within a consistent, CoA-verified supply chain.
Mechanistic Differentiation
| Compound | Receptor Targets | Key Mechanism Advantage | Phase 3 Peak Efficacy | Hepatic Fat Reduction | Energy Expenditure |
|---|---|---|---|---|---|
| Semaglutide SLIMERIX™ 5MG | GLP-1R only | Strong satiety, gastric emptying delay; most established clinical dataset | ~15% (STEP 1, 68wk) | Moderate (indirect) | Modest increase |
| Tirzepatide ZONJERO 30MG | GLP-1R + GIPR | GIPR co-agonism amplifies insulin secretion and adipose lipid partitioning | ~21% (SURMOUNT-1, 72wk) | Moderate–High | Moderate increase |
| Retatrutide REVYTAL 30MG | GLP-1R + GIPR + GCGR | GCGR activation drives direct hepatic fat oxidation and elevated basal energy expenditure — unique among this compound class | ~24.2% (Ph.2 NEJM, 48wk) | High (direct glucagon pathway) | Highest of the three |
Why the Glucagon Receptor Changes Everything
The glucagon receptor (GCGR) component is the mechanistic element that separates retatrutide from all prior GLP-1-class compounds. In isolation, GCGR agonism would elevate blood glucose — an unwanted effect. However, when co-administered with GLP-1R and GIPR agonism, the insulin-secreting activity of both counterbalances GCGR-mediated glucose elevation, allowing glucagon’s direct hepatic effects to be harnessed without glycaemic disruption. This pharmacological interplay is what the Nature Communications structural biology paper (2024) confirms at the molecular binding level.
Hepatic Research Implications
GCGR activation directly stimulates hepatic fatty acid oxidation (β-oxidation), reduces hepatic de novo lipogenesis, and increases energy expenditure at the cellular level. For researchers investigating non-alcoholic steatohepatitis (NASH), hepatic lipid metabolism, or energy homeostasis signalling, retatrutide provides a research tool that semaglutide and tirzepatide cannot replicate. The Phase 2 data documented reductions in liver fat fraction measured by MRI-PDFF — a readout of direct utility in hepatology research models.
Energy Expenditure Upregulation
Beyond hepatic effects, GCGR agonism in preclinical models has been associated with thermogenic activation in brown adipose tissue and upregulation of uncoupling protein 1 (UCP1) expression. For researchers investigating adipose biology, mitochondrial function, or metabolic rate modulation, this pathway represents a mechanistically distinct research vector not available through GLP-1 mono- or dual-agonist compounds.
For related reading on how these compounds compare across the weight-loss peptide class, see the Arma Peptides guide: Best Peptides for Weight Loss in 2026: Retatrutide, Semaglutide, Tirzepatide & More.
Source Retatrutide with Third-Party Verified Purity
RETATRUTIDE REVYTAL 30MG — ≥99% HPLC purity, independent CoA per batch, lyophilized powder, dispatched within 1–2 business days. First order: use FIRST10% at checkout.
Order Retatrutide REVYTAL 30MG — £130Full Research CatalogueTelegram Exclusive Deals
Retatrutide UK Supplier Comparison Table
The quality verification practices of UK peptide suppliers vary substantially. The table below benchmarks the key criteria researchers should evaluate when selecting a retatrutide supplier. One variable worth highlighting explicitly: UK Peptides has published a blog post titled “Why UK Peptides Doesn’t Use Third-Party Lab Testing” — their own copy confirms they rely on internal testing only, and their FAQ states: “We do not use third-party labs.” For researchers requiring independently verifiable purity data, this is a material difference.
| Supplier | Retatrutide In Stock | Third-Party CoA | Purity Standard | UK Dispatch | CoA Per Batch | Free Delivery Threshold |
|---|---|---|---|---|---|---|
| Arma Peptides ✓ CoA Verified | ✓ 30MG | ✓ Independent | ≥99% HPLC | 1–2 Business Days | ✓ Per Batch | £200 |
| UK Peptides | ✗ Not Stocked | ✗ In-house only* | ≥99% (claimed) | Same Day (before 3pm) | ✗ Generic CoA | Not stated |
| Peptides4U | ✓ 10MG / 30MG | Varies | Not stated | Not stated | Not confirmed | Not stated |
| Synergetics UK | ✓ | Not stated | Not stated | UK | Not confirmed | Not stated |
| Anglo Peptides | ✓ 40MG | “Test report pending” | Not stated | UK | ✗ Pending | Not stated |
*UK Peptides publicly states on their own blog and FAQ that they do not use third-party laboratory testing. Source: uk-peptides.com/blog/uk-peptides-testing-standard
RETATRUTIDE REVYTAL 30MG — Arma Peptides
Arma Peptides supplies RETATRUTIDE REVYTAL 30MG as a lyophilized (freeze-dried) powder in a sealed research vial. Each batch is accompanied by an independent, third-party Certificate of Analysis confirming ≥99% purity by HPLC — viewable at armapeptides.com/certificate-of-analysis/. This is not a shared or reused CoA from a prior batch; it is batch-specific documentation generated by an independent laboratory.
Featured — Triple Agonist
RETATRUTIDE REVYTAL 30MG
£130
≥99% HPLC Purity
Format: Lyophilized Powder
CoA: Independent, Per Batch
Dispatch: 1–2 Business Days
Targets: GLP-1R · GIPR · GCGR
GLP-1 Agonist
SLIMERIX™ 5MG (Semaglutide)
£120
≥99% HPLC Purity
Format: Lyophilized Powder
CoA: Independent, Per Batch
Dispatch: 1–2 Business Days
Target: GLP-1R
Dual GLP-1/GIP
ZONJERO 30MG (Tirzepatide)
£130
≥99% HPLC Purity
Format: Lyophilized Powder
CoA: Independent, Per Batch
Dispatch: 1–2 Business Days
Targets: GLP-1R · GIPR
Metabolic Support
NAD+
£120
≥99% HPLC Purity
Format: Lyophilized Powder
CoA: Independent, Per Batch
Dispatch: 1–2 Business Days
Research: Mitochondrial metabolism
Free UK & EU Delivery on orders over £200. Combine retatrutide with semaglutide or tirzepatide for comparative research programmes — all dispatched within 1–2 business days, tracked. View the full catalogue at armapeptides.com/shop.
Laboratory Sourcing Checklist: Evaluating a Retatrutide Supplier
When procuring retatrutide for UK laboratory research, the following verification steps should be applied to any prospective supplier before ordering. A Guardian investigation (April 2026) found approximately one-third of independently tested samples from unregulated peptide sources failed basic quality checks — a finding that underscores the importance of supplier-side verification rather than post-purchase testing alone. See also the Arma Peptides guide: Best Tested Peptide Suppliers: Quality-Verified Companies in 2026.
- Confirm the supplier provides a batch-specific Certificate of Analysis — not a generic or reused CoA from a previous production run
- Verify the CoA was generated by an independent third-party laboratory with no financial relationship to the supplier — not internal in-house testing
- Check the CoA includes both HPLC purity data (≥99% for research-grade) and mass spectrometry identity confirmation
- Confirm the product is supplied in lyophilized (freeze-dried) powder format — not pre-reconstituted, which reduces shelf stability
- Verify storage conditions during fulfilment: retatrutide should be stored and dispatched at appropriate temperatures, not ambient warehouse conditions
- Check that the supplier operates under a clear research-use-only framework with legal compliance documentation — not implicit or ambiguous product positioning
- Confirm tracked dispatch with realistic UK timelines — 1–2 business days for domestic UK supply is achievable and expected from established suppliers
- Assess contact accessibility: a legitimate supplier should be reachable via direct email (not solely through anonymous messaging apps) and should provide clear ordering, delivery, and returns policies
Order Retatrutide REVYTAL 30MG — UK’s Most Verified Supply
Every Arma Peptides order ships with an independent CoA, ≥99% HPLC purity, lyophilized format, and tracked 1–2 day UK dispatch. Orders over £200 qualify for free delivery. Questions? Email info@armapeptides.com
Order REVYTAL 30MG — £130Browse Full ShopTelegram — Exclusive Deals
First order? Use FIRST10% at checkout for 10% off.
FAQs — Retatrutide Research Peptide UK
What is retatrutide and how does it differ from semaglutide and tirzepatide?
Retatrutide (LY3437943) is a synthetic 39-amino-acid research peptide that simultaneously activates three hormone receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). Semaglutide activates GLP-1R only; tirzepatide activates GLP-1R and GIPR. The additional glucagon receptor agonism in retatrutide drives direct hepatic fat oxidation and elevated energy expenditure — mechanisms not present in either predecessor compound. In Phase 2 clinical trials, retatrutide demonstrated superior weight reduction efficacy versus both semaglutide (STEP 1) and tirzepatide (SURMOUNT-1) historical comparators. For research use only.
What did the retatrutide Phase 2 NEJM 2023 trial show?
The Phase 2 randomised controlled trial published in The New England Journal of Medicine (June 2023, DOI: 10.1056/NEJMoa2301972) enrolled adults with obesity across five once-weekly subcutaneous dose groups. At the highest dose (12mg) over 48 weeks, participants achieved a mean weight reduction of 24.2%, with approximately 85% of participants reaching ≥10% body weight loss and 76% reaching ≥15%. Significant reductions in waist circumference (up to −25.1cm) and hepatic fat fraction were also documented. Phase 3 trials (the TRIUMPH programme) are ongoing.
Can I buy retatrutide in the UK for laboratory research?
Yes — retatrutide is available from UK research peptide suppliers for in vitro and preclinical laboratory research use only. It is not licenced by the MHRA for clinical or human use. Arma Peptides supplies RETATRUTIDE REVYTAL 30MG at £130 with third-party verified CoA per batch, ≥99% HPLC purity, in lyophilized powder format. Dispatch within 1–2 business days, tracked, UK and EU delivery.
Why does third-party CoA verification matter when sourcing retatrutide?
Third-party testing means an independent laboratory — with no financial relationship to the supplier — has verified purity and molecular identity. In-house testing is conducted by the supplier themselves, creating a conflict of interest. UK Peptides, one of the UK’s larger peptide suppliers, publicly states on their own blog that they do not use third-party labs. Arma Peptides provides an independent CoA per batch, viewable at /certificate-of-analysis/. For researchers requiring reproducible, documented purity data for publication or institutional compliance, batch-specific independent CoAs are the appropriate standard.
What format is retatrutide supplied in and how should it be stored?
Arma Peptides supplies retatrutide in lyophilized (freeze-dried) powder format — the standard for research-grade peptides. Lyophilization removes water under vacuum, maximising shelf stability and resistance to degradation during transport. Once received, unopened lyophilized retatrutide should be stored at −20°C, protected from light and moisture. After reconstitution for research use, store at 2–8°C and use within the timeframe appropriate to the reconstitution vehicle and experimental protocol.
What other metabolic research peptides does Arma Peptides supply?
Arma Peptides stocks the full GLP-class research compound range alongside broader metabolic and regenerative research peptides: SLIMERIX™ 5MG (Semaglutide) — £120, ZONJERO 30MG (Tirzepatide) — £130, NAD+ — £120, MOTS-C 10MG — £70, BPC-157 & TB-500 Blend 20MG — £79, HGH 100 IU — £130, and GHK-Cu SKIN GLOW 100MG — £70. All products carry independent, batch-specific CoA documentation. View the full range at armapeptides.com/shop.
Research Use Only Disclaimer: All peptide compounds referenced on this page are supplied exclusively for laboratory research and scientific investigation purposes. These products are not intended for human or animal consumption, and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Retatrutide is an investigational compound not licensed by the MHRA or any regulatory authority for human use. Arma Peptides products are intended solely for use by qualified researchers and laboratory professionals operating within applicable legal and institutional frameworks. Users are responsible for ensuring compliance with all relevant laws and regulations governing the purchase, storage, and use of research compounds in their jurisdiction. This content is for informational purposes and does not constitute medical, clinical, or pharmaceutical advice.
Add comment